Bone loss with antiepileptic drug therapy: A twin and sibling study
Journal article
Ahmad, B. Shiek, Petty, Sandra J., Gorelik, Alex, O'Brien, Terence J., Hill, K. D., Christie, J. J., Sambrook, Philip N. and Wark, John D.. (2017). Bone loss with antiepileptic drug therapy: A twin and sibling study. Osteoporosis International. 28(9), pp. 2591 - 2600. https://doi.org/10.1007/s00198-017-4098-9
Authors | Ahmad, B. Shiek, Petty, Sandra J., Gorelik, Alex, O'Brien, Terence J., Hill, K. D., Christie, J. J., Sambrook, Philip N. and Wark, John D. |
---|---|
Abstract | Summary Changes in areal bone mineral density (aBMD) and other predictors of bone loss were evaluated in 48 same-sex twin/age-matched sibling pairs discordant for antiepileptic drug (AED) use. AED users had reduced BMD at the hip regions. Prolonged AED users had greater aBMD loss, predicting a higher risk of bone fragility. Introduction To investigate the longitudinal associations of bone mineral measures with antiepileptic drug (AED) use, including enzyme-inducing (EIAED) and non-enzyme-inducing (NEIAED) types, and other predictors of bone loss in a study of 48 same-sex twin/age-matched sibling pairs (40 female, 8 male) discordant for AED use. Methods Using dual-energy X-ray absorptiometry (DXA), areal bone mineral density (aBMD) and content (BMC) at the hip regions, forearm, lumbar spine, and whole body were measured twice, at least 2 years apart. The mean within-pair difference (MWPD), MWPD%, and mean annual rate of aBMD change were adjusted for age, weight, and height. Predictors of bone loss were evaluated. Results AED users, compared to non-users, at baseline and follow-up, respectively, had reduced aBMD at the total hip (MWPD% 3.8, 4.4%), femoral neck (4.7, 4.5%), and trochanter regions (4.1, 4.6%) (p < 0.05). For the whole cohort, the annual rate of change in all aBMD/BMC (p > 0.05) regions did not differ within pairs. Nevertheless, EIAED users had greater aBMD loss than non-users (n = 20 pairs) at the total hip (1.7 vs. 0.3%, p = 0.013) and whole body regions (0.7% loss vs. 0.1% BMD gain, p = 0.019), which was not found in NEIAED-discordant pairs (n = 16). AED use >20 years predicted higher aBMD loss at the forearm (p = 0.028), whole body (p = 0.010), and whole body BMC (p = 0.031). Conclusions AED users had reduced aBMD at the hip regions. Prolonged users and EIAED users had greater aBMD loss, predicting a higher risk of bone fragility. Further prospective studies of AED effects on bone microarchitecture are needed. |
Keywords | antiepileptic drug; bone mineral density (BMD); dual-energy x-ray absorptiometry (DXA); epilepsy; longitudinal study |
Year | 2017 |
Journal | Osteoporosis International |
Journal citation | 28 (9), pp. 2591 - 2600 |
Publisher | Springer London |
ISSN | 0937-941X |
Digital Object Identifier (DOI) | https://doi.org/10.1007/s00198-017-4098-9 |
Scopus EID | 2-s2.0-85020279469 |
Page range | 2591 - 2600 |
Publisher's version | File Access Level Controlled |
Grant ID | NHMRC/400089 |
Place of publication | United Kingdom |
https://acuresearchbank.acu.edu.au/item/89vyx/bone-loss-with-antiepileptic-drug-therapy-a-twin-and-sibling-study
Restricted files
Publisher's version
113
total views0
total downloads0
views this month0
downloads this month